BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Betta Pharmaceuticals Co. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Betta Pharmaceuticals Co.'s drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06885840-2050@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pamvatamig: Phase 2 readout est. (NCT06885840)
DESCRIPTION:Pamvatamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with
  AGA and MET Amplification.\nEstimated primary completion: April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pamvatamig#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06885840
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04930432-2050@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pamvatamig: Phase 1/2 readout est. (NCT04930432)
DESCRIPTION:Pamvatamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of MCLA-129\, a Human Bispecific EGFR and cMet Antibody\, in Patients 
 With Advanced NSCLC and Other Solid Tumors\nEstimated primary completion: 
 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pamvat
 amig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04930432
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06041776-2235@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Befotertinib: Phase 3 readout est. (NCT06041776)
DESCRIPTION:Befotertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 juvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Posit
 ive EGFR Sensitive Mutations\nEstimated primary completion: 30 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/befotertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06041776
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181499-2235@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Befotertinib: Phase 2 readout est. (NCT07181499)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Se
 quential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSC
 LC) Patients With Resistance to Third-Generation EGFR-TKI\nEstimated prima
 ry completion: November 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/befotertinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07181499
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07435038-2419@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20281228
DTEND;VALUE=DATE:20281229
SUMMARY:BPI-572270: Phase 1/2 readout est. (NCT07435038)
DESCRIPTION:BPI-572270\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specifi
 c Mutations in RAS\nEstimated primary completion: 28 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bpi-572270#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07435038
URL:https://assetmemo.bio/drug/bpi-572270#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07448116-1978@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Ensacove (Ensartinib): Phase 1/2 readout est. (NCT07448116)
DESCRIPTION:Ensacove (Ensartinib)\, phase 1/2.\nStudy: Study of MCLA-129 in
  Combination With Ensartinib in Patients With Advanced Solid Tumors.\nEsti
 mated primary completion: 1 February 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ensartinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07448116
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
